Nordic Therapeutic Alliance (NTA)
| Reference number | |
| Coordinator | Cytiva Testa Center AB |
| Funding from Vinnova | SEK 1 496 000 |
| Project duration | October 2025 - March 2026 |
| Status | Ongoing |
| Venture | Cluster of Excellence for Cutting-Edge Technologies - calls for proposals |
| Call | Visions for world-leading research and innovation in strategic technology areas |
Purpose and goal
Nordic Therapeutic Alliance brings together 35 leading actors to establish Sweden, and the Nordic region, as a global leader in innovative precision therapies. Through cutting-edge technologies such as AI, robotics and 3D printing, and transdisciplinary collaboration across sectors, disciplines and national borders, the entire value chain – from research to patient – is being developed to radically reduce lead times, lower costs and increase access to advanced treatments, nationally and globally
Expected effects and result
This pre-project builds the foundation for a future excellence cluster by forming a dedicated and goal-oriented consortium covering the full value chain including emerging technologies to be applied; aligning on ambitious measurable goals; proposing a program office with organization, governance and roles; identifying high-impact challenges and opportunities along the value chain; establishing expert groups for domain-specific projects and presenting a plan, budget, and long-term strategy.
Planned approach and implementation
This project applies a holistic approach addressing the full value chain from academic research to patient-ready treatments, combining system-level thinking with cutting-edge technologies to tackle bottlenecks and inefficiencies through cross-sector collaboration. It applies high tech areas directly to drug development and production aiming to reduce lead times, lower costs and improve access to advanced therapies to create impact: better patient outcomes, new jobs and increased export revenues.